The present paper reports that 8-dimethyl-4-hydroxymethyl-1(2H)-phthalazinone) (Nippon Kayaku Co., Tokyo) prevented aggregation of rabbit platelets in vitro by ADP, collagen and arachidonic acid, and potentiated remarkably an antiaggregatory action of prostacyclin (PGI2). Platelet rich plasma (PRP) was prepared by centrifugation (200 xg, 15 min) of rabbit blood, collected under ether anesthesia through the carotid artery into plastic tubes, containing 1/10 volume of 3.8% sodium citrate.Platelet poor plasma (PPP) was obtained by centrifugation (2, 000 xg, 15 min) of PRP.Aggregation of platelets (4-7 x 105/il) was recorded by the light transmission (PRP= 0%, PPP=100%) using an aggregometer (RAM, Rikadenki Kogyo, Ltd., Tokyo).
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EG-626 (100-300 pM) inhibited does-dependently an aggregation by arachidonic acid (100-500pM), collagen (5-20 pg/ml) or ADP (0.3-100 pM).ID5o values against the maximum doses of the aggregating agents were about 88, 110 and 300 pM, respectively.The aggregation by arachidonic acid (400 pM), collagen (20pg/ml) or ADP (30 pM) was also inhibited by increasing doses (0.1-50 nM) of PGI2•Na (Ono Pharmaceutical Co., Osaka) and ID50 values were about 22, 10 and 7 nM, respectively. Combination of EG-626 and PGI2.Na in threshold doses considerably potentiated the inhibitory effects of each inhibitor on the aggregation by ADP or collagen.The aggregation by ADP (30 pM) was inhibited by 72% of the control by 1.4 nM PGI2+50pM EG-626, 67% by 0.4 nM PG1+100pM EG-626 and 100 % by 1.4 nM PGI2+100 pM EG-626.Smaller dose (50 pM) of EG-626, when added to PGI2 (3 nM), also completely prevented the aggregation by collagen (20 pg/ml).The potentiating effect of EG-626 on PGI2 may be due to an inhibition of phosphodiesterase, since PGI2 is known to activate adenylate cyclase. 10: 461 
